Rosa Rosario

University of Central Florida — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

27h-index2.7kcitations104works0.52yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Glycation End Products research(36), Mosquito-borne diseases and control(31), Virus-based gene therapy research(19), Neuroblastoma Research and Treatments(15), Atherosclerosis and Cardiovascular Diseases(11)

Publications104 total

Perianal tuberculosis presenting as a Fournier's gangrene

2 cited

Clinical Case Reports·2024· 2 citedOpen Access

Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis

5 cited

Oncogene·2024· 5 citedOpen Access

Supplementary Figure 3 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

FIGURE 5 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 3 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

FIGURE 3 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 7 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

FIGURE 4 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 5 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Data from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

FIGURE 6 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 5 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 1 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 8 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 2 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 8 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

FIGURE 1 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 6 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 4 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

FIGURE 2 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

page 1 of 6Next →

Frequent Co-authors

Ann Marie Schmidt(25), Ravichandran Ramasamy(16), Shi Fang Yan(14), Radha Ananthakrishnan(12), Xiaoping Shen(9), Fei Song(9), Yan Lü(6), Yu Zou(5), Richard A. Friedman(5), Wu Qu(5), José António Lopes(5), Huilin Li(4), Nosirudeen Quadri(4), Vivek Rai(4), Vivette D. D’Agati(4), Fatouma Touré(4), Jinghua Zhang(4), Gurdip Daffu(4), Joana Gameiro(4), Sofía Jorge(4)